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Background: Medication-overuse headache (MOH) is a frequent, disabling disorder. Despite a controversial
pathophysiology convincing evidence attributes a pivotal role to central sensitization. Most patients with MOH
initially have episodic migraine without aura (MOA) characterized interictally by an absent amplitude decrease in
cortical evoked potentials to repetitive stimuli (habituation deficit), despite a normal initial amplitude (lack of
sensitization). Whether central sensitization alters this electrophysiological profile is unknown. We therefore sought
differences in somatosensory evoked potential (SEP) sensitization and habituation in patients with MOH and
episodic MOA.
Methods: We recorded median-nerve SEPs (3 blocks of 100 sweeps) in 29 patients with MOH, 64 with MOA and
42 controls. Episodic migraineurs were studied during and between attacks. We measured N20-P25 amplitudes
from 3 blocks of 100 sweeps, and assessed sensitization from block 1 amplitude, and habituation from amplitude
changes between the 3 sequential blocks.
Results: In episodic migraineurs, interictal SEP amplitudes were normal in block 1, but thereafter failed to
habituate. Ictal SEP amplitudes increased in block 1, then habituated normally. Patients with MOH had larger-
amplitude block 1 SEPs than controls, and also lacked SEP habituation. SEP amplitudes were smaller in triptan
overusers than in patients overusing nonsteroidal anti-inflammatory drugs (NSAIDs) or both medications combined,
lowest in patients with the longest migraine history, and highest in those with the longest-lasting headache
chronification.
Conclusions: In patients with MOH, especially those overusing NSAIDs, the somatosensory cortex becomes
increasingly sensitized. Sensory sensitization might add to the behavioral sensitization that favors compulsive drug
intake, and may reflect drug-induced changes in central serotoninergic transmission.
Background
Medication-overuse headache (MOH) is a complication
of episodic headaches characterized by more than 15
headache days per month and arising from an excessive
intake of analgesics or specific anti-migraine drugs, or
both [1]. MOH is a disabling health problem that affects
2-4% of the general population and causes considerable
long-term morbidity and disability [2]. Most patients
attending headache clinics for chronic daily headache
have MOH [1,3]. Although MOH evolves from primary
as well as secondary headaches the most prevalent initial
headache type is episodic migraine without aura and
most patients return to the episodic pattern after drug
withdrawal [1].
How and why medication overuse leads to chronic
episodic headache is unknown. Possible culprits for pain
chronification include central sensitization and defective
central pain control systems [4]. The addictive behavior
and high relapse rates after withdrawal may depend on
orbitofrontal cortex hypofunction [5]. The observation
that MOH develops predominantly in migraineurs with-
out aura suggests that this headache type possesses
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without aura repeated sensory stimuli delivered using
various modalities elicit abnormal cortical responses
characterized by deficient habituation contrasting with a
normal-amplitude initial evoked potential elicited by a
small number of stimuli [6]. Current hypotheses attri-
bute this neurophysiological abnormality to cortical
hyper-excitability probably arising from deficient intra-
cortical inhibition [7], or to low sensory cortical pre-
activation levels ultimately due to abnormal functioning
of monoaminergic projections from the brainstem [6,8].
Habituation is considered a protective mechanism
intended to prevent neuronal stress and excessive accu-
mulation of metabolites such as lactate and protons that
are likely to induce cortical spreading depression or tri-
geminovascular activation, or both. Evidence suggesting
that lack of habituation can promote migraine attacks
comes from the observation that it culminates just
before the onset of an attack, in the pre-ictal phase
[9-11]. During the attack, habituation normalizes, thus
transiently activating the protective mechanisms thought
to prevent attack recurrence [10-14].
A neurophysiological technique ideally suited to inves-
tigate how sensory cortices respond to repetitive stimu-
lation consists of testing somatosensory evoked
potentials (SEPs). SEPs are obtained by weak sensory
stimuli ideal for disclosing sensitization (reflected by an
increased response amplitude to low numbers of
stimuli) and habituation (reflected by a decrease in
response amplitude after high numbers of stimuli)
[15,16], and proved highly sensitive in disclosing abnor-
mal habituation in migraineurs studied interictally, i.e. a
clear-cut lack of habituation from the 2
nd block of aver-
aged responses onwards [17]. To the best of our knowl-
edge no study has investigated SEP sensitization and
habituation in patients with MOH. Having this informa-
tion may shed light on the mechanisms underlying
headache chronification during acute medication
overuse.
We used therefore SEPs to investigate whether medi-
cation overuse sensitizes the sensory cortices, whether
sensitization varies according to the drug overused, and
whether the cortical response patterns, sensitization and
habituation, differ between patients with episodic
migraine without aura recorded in ictal and interictal
phases and those with MOH. We also sought possible
correlations between the electrophysiological patterns
and clinical features including duration of migraine his-
tory, duration of headache chronification and class of
drugs overused.
Methods
Subjects-Among consecutive patients attending our
headache clinic, 93 patients gave informed consent to
participate in the study (Table 1), which was approved
by the local ethics committee.
According to the revised ICHD-II criteria [1], 29
patients (35 ± 11 years; 23 women) were diagnosed as
having MOH during their first visit, a diagnosis that
was confirmed 2 months after withdrawal treatment.
These patients were stratified according to the class of
drug overused: triptans (n = 9), nonsteroidal antiin-
flammatory drugs (NSAIDs) (n = 10) or a combination
of both (n = 10). Before progressing to MOH, all
patients had a clear-cut history of episodic migraine
w i t h o u ta u r a( I C H D - I Ic o d e1 . 1 ) .W i t ht h ee x c e p t i o n
of 2 patients who had a mild headache, all MOH
patients (n = 27) underwent the SEP recordings in a
pain-free state. The 2 patients who had a headache
had no associated migrainous features. Because MOH
patients tend to take acute medications compulsively
and frequently during the day, it was impossible to
prevent them from taking a medication on the day of
recordings. We managed, however, to perform the
recordings at least 3 hours after last medication intake.
T h e6 4p a t i e n t sw h oh a de p i s o d i cm i g r a i n ew i t h o u t
aura (ICHD-II code 1.1) were assigned to two sub-
groups: 41 patients (34 ± 9 years; 23 women) were
recorded during the interictal period, i.e. at least three
days before and after an attack, and 23 patients (33 ±
12 years; 20 women) during the ictal period, i.e. from
12 hours before to 12 hours after an attack. The latter
were not allowed to take any acute medication before
the end of recordings.
For comparison we recorded SEPs in 42 healthy
volunteers of comparable age and sex distribution
(mean age: 33 ± 13; 26 women); they had no personal
or familial history (1st or 2nd degree relatives) of
migraine and no detectable medical condition.
To avoid variability due to hormonal changes, women
were recorded outside their pre-menstrual or menstrual
periods.
Data acquisition
SEPs were elicited by electrical stimulation applied to
the right median nerve at the wrist using a constant cur-
rent square wave pulse (0.1 ms width, cathode proxi-
mal), a stimulus intensity set at 1.5 times the motor
threshold, and a repetition rate of 4.4 Hz. The active
electrodes were placed over the contralateral parietal
area (C3’,2c mp o s t e r i o rt oC 3i nt h eI n t e r n a t i o n a l
10-20 system) and on the fifth cervical spinous process
(Cv5), both referenced to Fz; the ground electrode was
on the right arm [18]. SEP signals were amplified with a
Digitimer™ D360 pre-amplifier (Digitimer Ltd, UK)
(band-pass 0.05-2500 Hz, Gain 1000) and recorded with
a CED™ power1401 device (Cambridge Electronic Design
Ltd, Cambridge, UK).
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Page 2 of 9Subjects sat relaxed in a comfortable chair in a well-lit
room with eyes open. They were asked to fix attention
on the stimulus-induced thumb movement. During con-
tinuous median-nerve stimulation at the wrist, we
collected 300 sweeps of 50 ms, sampled at 5000 Hz. All
recordings were averaged off-line using the Signal™ soft-
ware package version 3.10 (CED Ltd).
Three hundred artefact-free evoked responses
recorded in each subject were averaged ("grand aver-
age”). After digital filtering of the signal between 0-450
Hz, the various SEP components (N13, N20, P25 and
N33) were identified according to their respective laten-
cies. We measured peak-to-peak amplitudes of the cer-
vical N13 component (recorded under the active Cv5
electrode), and the cortical N20-P25 and P25-N33 com-
ponents (recorded under the active C3’ scalp electrode).
Thereafter, the 300 evoked responses were partitioned
in 3 sequential blocks of 100 responses (Figure 1). Each
block was averaged off-line ("block averages”) and ana-
lyzed for N20-P25 amplitudes. Sensitization was defined
as an increased N20-P25 amplitude recorded during
block 1 (after a low number of 100 stimuli), whereas
habituation was expressed as the change in N20-P25
amplitude in blocks 2 and 3 compared to block 1 (over
a high number of 300 repetitive stimuli).
Statistical Methods
We used the Statistical Package for the Social Sciences
(SPSS) for Windows, version 15.0 for all analyses. For
grand average SEPs, component amplitudes were tested
in a one-way analysis of variance (ANOVA) with group
factor “subjects” (MOH patients, episodic migraineurs
without aura studied ictally or interictally, and healthy
subjects). To assess changes in SEP amplitude between
b l o c k s1 ,2a n d3S E PN 2 0 - P 2 5a m p l i t u d e sw e r et e s t e d
first with a repeated-measure ANOVA with group factor
“subjects” and repeated measures factor “block” then
using as group factor “MOH subgroups” (MOH-triptans,
MOH-NSAIDs, MOH-combination, and normal sub-
jects). Tukey’s test was used for post hoc analyses. Pear-
son’s correlation coefficient was calculated to test
correlations between SEP amplitudes or habituation and
clinical data (disease duration, days with headache, num-
ber of tablets taken per month, duration of chronic
headache). P values less than 0.05 were considered to
indicate statistical significance.
Results
Assessable SEP recordings were obtained from all patients
and controls participating in the study (Figure 1). On
grand average SEP recordings after electrical median nerve
stimulation latencies of N13, N20, P25 and N33 compo-
nents were not different between groups (for each
measure F(3,131), p > 0.05) whereas their amplitudes
significantly differed between groups (F(3,131) = 2.75,
p = 0.045). Post hoc analysis showed a higher N20-P25
amplitude in patients with MOH and migraineurs without
aura studied ictally than in the subgroup studied interic-
tally and controls (Figure 2).
ANOVA testing SEP amplitude block averages
disclosed a main effect for factors group (F(3,131) =
3.83, p = 0.01) and block (F(2,262) = 4.13, p = 0.017),
and a significant interaction of group by block
(F(6,262) = 2.42, p = 0.027). Post hoc analysis showed
in each block a higher N20-P25 amplitude in patients
with MOH and migraineurs without aura studied
ictally than in the subgroup studied interictally and
controls (Figure 3). In controls and migraineurs with-
out aura studied ictally, N20-P25 amplitude decreased
from block 1 to block 3, i.e. habituated, while in















Women (n) 26 23 20 23 7 8 8
Age (years) 32 ± 13 34 ± 9 33 ± 12 35 ± 11 32 ± 8 35 ± 9 34 ± 12
Duration of history of migraine (years) 18.0 ± 12.7 16.7 ± 10.9 18.4 ± 11.0 18.3 ± 9.6 22.4 ± 9.2 13.0 ± 13.7
Days with headache/month (n) 2.1 ± 1.9 3.5 ± 2.3 25.9 ± 6.1 22.1 ± 6.2 25.0 ± 7.4 29.4 ± 1.6
Severity of headache attacks (0-10) 6.8 ± 0.8 7.2 ± 1.2 7.2 ± 0.8 7.4 ± 1.1 7.2 ± 0.5 7.1 ± 0.8
Nausea/vomiting (n) 25 16 24 8 9 7
Photophobia (n) 37 21 27 8 10 9
Phonophobia (n) 31 20 27 7 10 10
Pulsating (n) 38 21 26 9 9 8
Duration of the chronic headache (years) 3.0 ± 3.2 1.9 ± 1.8 3.5 ± 3.1 3.3 ± 3.9
Tablet intake/month (n) 74.2 ± 80.8 28.7 ± 16.3 50.5 ± 38.5 127.3 ± 106.5
Motor threshold (mA) 8.4 ± 1.3 8.6 ± 1.3 8.5 ± 1.5 8.7 ± 1.2 8.8 ± 1.3 9.1 ± 1.1 8.3 ± 1.1
Data expressed as mean ± SD. HV healthy volunteers; MOii episodic migraneurs without aura studied interictally; MOi episodic migraneurs without aura studied
ictally; N number of subjects.
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Page 3 of 9patients with MOH and migraineurs with aura studied
interictally it remained unchanged from block 2
onwards, i.e. did not habituate.
Conversely, ANOVA testing block 1 SEP amplitudes
showed a main effect only for factor group (F(3,131) =
2.73, p = 0.046) (Figure 3). Post hoc analysis showed
that N20-P25 amplitudes were higher in patients with
MOH and migraineurs without aura studied ictally than
in the subgroup studied interictally and controls.
When we stratified the data for patients with MOH
according to the class of drugs overused, triptans,
NSAIDs or both combined, ANOVA for SEP amplitudes
in the various blocks, showed a main effect for factor
“drug” (F(2,26) = 3.57, p = 0.042). Post hoc analysis dis-
closed smaller N20-P25 amplitudes in patients overusing
triptans than in those overusing NSAIDs or both medi-
cations combined. In addition, group analysis between
triptan overusers and controls showed that the N20-P25
amplitude in block 1 was normal in patients (F(1,49) =
1.08, p = 0.3) (Figure 4).
Pearson’s test disclosed various correlations between
SEP amplitude and clinical variables. In patients with
MOH, N20-P25 amplitude on SEP grand average corre-
lated negatively with disease duration (i.e. combined
duration of episodic and chronic headache phases,
r = -0.411, p = 0.046). Conversely, grand average N20-
P25 amplitude (r = 0.477, p = 0.016) as well as block 1
N20-P25 amplitude (r = 0.454, p = 0.023) correlated
positively with duration of the chronic headache phase.
Discussion
The distinct changes we found in cortical responses to
low and high numbers of sensory stimuli in patients
with MOH suggest that the underlying brain mechan-
isms are altered and differ from those acting in patients
with episodic migraine without aura. Low numbers of
Figure 1 Illustrative traces of somatosensory evoked potentials habituation in a healthy volunteer, MO Interictally and ictally, and
MOH patient.
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Page 4 of 9Figure 2 Somatosensory evoked potential (SEP) amplitude grand average in each study group (HV, healthy volunteers; MOii, migraine
without aura interictally; MOi, migraine without aura Ictally; MOH, medication overuse headache; data expressed as mean ± SEM).
Figure 3 Somatosensory evoked potential (SEP) amplitude block averages in each study group (HV, healthy volunteers; MOii, migraine
without aura interictally; MOi, migraine without aura Ictally; MOH, medication overuse headache; data expressed as mean ± SEM).
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Page 5 of 9median nerve electrical stimuli (block 1) disclosed
sensory cortex sensitization in patients with MOH and in
episodic migraineurs recorded ictally, whereas amplitude
changes over sequential block averagings were consistent
with habituation in healthy volunteers and episodic
migraineurs recorded ictally, but not in MOH patients
and episodic migraineurs recorded interictally. In MOH
patients, SEP amplitude was lowest in those with the
longest history of migraine, whereas it was highest in
those with the longest period of headache chronification,
suggesting that the electrophysiologic changes reflect
chronification. Patients who overused triptans had lower
SEP amplitudes than those who overused NSAIDs or
both anti-migraine medications combined, indicating
that sensitization varies according to the drug overused.
The combination of an initial SEP amplitude increase
(sensitization) along with the subsequent lack of habi-
tuation suggests that the electrophysiological pattern
underlying MOH differs from that underlying episodic
migraine. In episodic migraine, SEP recordings show
two characteristic changes: a lack of habituation on
interictal recordings, and sensitization during the attack.
The habituation deficit normalizes during attacks,
whereas sensitization disappears between attacks, but in
the immediate pre-ictal phase both sensitization and
absent habituation may co-exist [9-11]. The electrophy-
siological pattern we found in MOH may therefore sug-
gest that the sensory cortex is locked in a pre-ictal state
associating both hyper-sensitivity (due to sensitization)
and hyper-responsiveness (due to deficient habituation),
which contrasts with episodic migraine where these cor-
tical states alternate. It is likely that the disclosure of
this peculiar electrophysiological pattern was made pos-
sible by the fact that we avoided to record MOH
patients during a full-blown migraine attack. The SEP
pattern associating sensitization and lack of habituation
that we compared with a “persistent pre-ictal state”,c l o -
sely resembles the response patterns generated by cen-
tral sensitized neuronal circuits. Sensitization refers to a
facilitatory process that competes with its opposite,
habituation to determine the final behavioural outcome
after stimulus repetition. This has been called the “dual
process” theory [15,16]. Illustrative of central sensitiza-
tion are the plastic changes in neural structures belong-
ing to the “pain matrix” [19] that result in decreased
nociceptive thresholds and increased responsiveness to
noxious and innocuous peripheral stimuli [20]. Studies
in animals [21] and humans [22] show that SEP ampli-
tudes increase when transient intense activation of noci-
ceptive afferents induces central sensitization, as
Figure 4 Somatosensory evoked potential (SEP) amplitude block averages in patients with medication overuse headache (MOH)
subgroups and a healthy volunteer (HV) (data expressed as mean ± SEM).
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Page 6 of 9happens in clinical pain conditions including chronic
headache. Our study shows that sensitization, as
reflected by increased initial SEP amplitudes, is common
to MOH and migraine attacks, although we did not
record MOH patients during an attack. A clinical conse-
quence of central sensitization is cutaneous allodynia. It
was shown to be prevalent during episodic migraine
attacks at cephalic and extracephalic sites [23,24], but
even more so in chronic migraine [25]. It is associated
with increased nociceptive reflexes [26,27], but, interest-
ingly, in MOH trigeminal evoked potentials were
increased, whereas nociceptive blink reflexes remained
unchanged, suggesting as in our study that sensitization
takes place at supraspinal levels [28].
Our finding that the SEP amplitude increase in MOH
is proportional to the duration of headache chronifica-
tion suggests that medication overuse and increased
headache frequency promote or reinforce central sensiti-
zation, but leaves open the question of the culprit. Con-
versely, since total duratio no ft h em i g r a i n ed i s o r d e r
correlates inversely with SEP amplitudes, the SEP ampli-
tude increase is likely related to factors other than
migraine duration and simply repetition of attacks. In
keeping with this interpretation, patients who overused
triptans alone had no initial SEP amplitude increase
indicating that the major culprit for central sensitization
in MOH could be NSAIDs. The neurobiological under-
pinning for this difference remains to be determined.
An observation that might favour of NSAIDs consump-
tion as a factor promoting sensitization is that NSAIDs
increase spinal expression of inducible cyclo-oxygenase-
2 [29], an enzyme that contributes to sensitization in a
rat model of inflammatory pain [30].
Another possible link between central sensitization,
migraine and anti-migraine drugs is monoaminergic
transmission in the central nervous system (CNS).
Although both triptan and NSAID overuse lead to head-
ache chronification, only the latter is accompanied by
SEP sensitization. We hypothesize that this difference is
due to a more profound decrease of 5-HT transmission
after NSAID overuse. Between attacks, migraine patients
have low blood 5-HT levels whereas the reverse is true
ictally [31]. Serotonin synthesis in the brain increases
during attacks, and this increase is partly counteracted
by acute triptan treatment [32]. Chronic administration
of triptans in rats, however, increases 5-HT synthesis in
several cortical projection areas of the dorsal raphe
nucleus [33] possibly reflecting down-regulation or
desensitization of 5-HT1 receptors. By contrast, in rats
chronically treated with analgesics, 5-HT2A receptors
are down-regulated [34] and the 5-HT transporter is
up-regulated in the cortex [34] and in platelets [35].
Upregulated platelet 5-HT transporters [35] and
decreased whole blood 5-HT levels [36] tend to
normalize after drug withdrawal. Collectively, these
experimental data suggest that anti-migraine drug over-
use can disrupt central 5-HT transmission. In chronic
triptan overuse both pre- and postsynaptic 5-HT1
receptors may become desensitised with the ensuing net
effect that serotonergic transmission may be only mildly
impaired. During analgesic and NSAID overuse, how-
ever, the combination of receptor desensitisation and
transporter upregulation may lead to serotonergic
hypoactivity. Together with noradrenaline and dopa-
mine, serotonin is crucial for tuning cortical excitability
including sensitization and habituation processes and its
effect in animals varies with concentration and duration
of application [37]. A more severe hypofunction of 5-
HT transmission after NSAID overuse may thus explain
the SEP sensitisation observed in this subgroup of MOH
patients. Whether the difference between the drug
classes with regard to central sensitisation is related to
the clinical observation that withdrawal headache is
much shorter after triptan than after analgesic overuse
[38] remains to be determined in a properly designed
prospective study comparing clinical outcome and elec-
trophysiological patterns.
The association of electrophysiological sensitisation, i.
e. increased 1
st block SEP amplitude, and lack of habi-
tuation.in MOH patients overusing NSAIDs is intri-
guing. It is at odds with the electrophysiological pattern
associating high amplitude in 1
st block and normal habi-
tuation found during migraine attacks [10-14], but, as
mentioned before, it has been described in the pre-ictal
phase [9-11]. One possible explanation for the lack of
habituation in episodic migraineurs between attacks is
the “ceiling theory” [39] postulating that there is a low
preactivation level of sensory cortices, also responsible
for the low 1
st block amplitudes, would allow a larger
range of activation before habituation occurs [6,8]. The
habituation deficit in NSAIDs overusers cannot be
explained by the “ceiling theory” since their high 1
st
block amplitude indicates rather that the somatosensory
cortex is sensitised. There is at present no straight for-
ward explanation for this pattern. It is likely, however,
that other neurobiological mechanisms that participate in
the production of habituation are impaired. For instance,
inhibitory interneurons could be hypofunctioning
because of the reduction in serotonergic transmission
induced by the prolonged NSAID overconsumption. This
hypothesis can be tested experimentally by searching if
habituation normalizes during full-blown attacks in
MOH patients like in episodic migraine and by exploring
inhibitory cortical interneurons with dedicated neurophy-
siological studies such as that of cortical silent periods
using transcranial magnetic stimulation. Given the simi-
lar neural mechanisms underlying sensory and beha-
vioural sensitization [40], the interesting question arises
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parallels behavioural sensitization. Behavioural sensitiza-
tion is paradigmatic of how the serotonergic, dopaminer-
gic, and noradrenergic systems interact and contribute to
central sensitization [41]. Brain circuits involved in addic-
tive behaviour include ventral and dorsal striatum, amyg-
dala and orbitofrontal cortex and are heavily modulated
by dopaminergic projections from the ventral tegmental
area of the midbrain, serotonergic projections from the
median and dorsal raphe nuclei, and noradrenergic pro-
jections from the locus coeruleus [4,42]. According to
DSM-IV criteria, many MOH patients manifest a depen-
dence behaviour [43]. The latter has been associated with
orbito-frontal cortex hypoactivity [44], an abnormality
also found in subgroups of MOH patients [5]. The
orbito-frontal cortex is thought to modulate habituation
mechanisms [45] and orbito-frontal lesions induce SEP
sensitization and lack of habituation [46], precisely the
two sensory abnormalities we found in patients with
MOH. Our findings along with current knowledge on the
neurobiology of drug overuse therefore suggest that
future studies seeking correlations between electrophy-
siological and metabolic measures should focus on the
orbito-frontal cortex. In our study we did not control for
associated depression and anxiety. Despite the evidence
that cortical pain-related evoked potentials in MOH do
not differ between subgroups of patients with or without
depressive symptoms [28], it may still be appropriate to
control for psychiatric comorbidity in future studies.
Conclusions
Cortical responses to repetitive sensory stimuli are
abnormal in patients with MOH. Increased response
amplitudes after low numbers of stimuli indicate sensory
sensitization and lack of amplitude decrease during sub-
sequent stimulations reflects a habituation deficit. This
cortical response pattern is similar the one found in the
immediate pre-ictal phase in episodic migraine, but dif-
ferent from the interictal and ictal patterns. It suggests
that the somatosensory cortex has become persistently
sensitized and that the migraine generating mechanisms
in the central nervous system are not shut off. The sen-
sitization is obvious in patients overusing NSAIDs and
almost non-existent or masked in those who overuse
only triptans. The different electrophysiological pattern
between drug classes may be related to the clinical
observation that withdrawal headache is shorter lasting
in triptan overusers than in NSAID overusers. We pos-
tulate that the abnormal sensory processing in MOH
patients reflects a drug-induced impairment of central
serotonin neurotransmission, that the decrease of sero-
tonergic activity is more profound after chronic
NSAID overconsumption and that the cortical sensory
sensitization parallels the behavioural sensitization that
accompanies drug overuse and is crucially modulated
by the medial orbitofrontal cortex.
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